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Translation initiationThe human embryonic-lethal abnormal vision (ELAV)-like protein, HuR, has been recently found to be
involved in the regulation of protein synthesis. In this study we show that HuR participates in the
translational control of the HIV-1 and HCV IRES elements. HuR functions as a repressor of HIV-1 IRES activity
and acts as an activator of the HCV IRES. The effect of HuR was evaluated in three independent experimental
systems, rabbit reticulocyte lysate, HeLa cells, and Xenopus laevis oocytes, using both overexpression and
knockdown approaches. Furthermore, results suggest that HuR mediated regulation of HIV-1 and HCV IRESes
does not require direct binding of the protein to the RNA nor does it need the nuclear translocation of the
IRES-containing RNAs. Finally, we show that HuR has a negative impact on post-integration steps of the HIV-
1 replication cycle. Thus, our observations yield novel insights into the role of HuR in the post-transcriptional
regulation of HCV and HIV-1 gene expression.
© 2009 Elsevier Inc. All rights reserved.Introduction
Initiation of protein synthesis in the eukaryotic cell is a complex
process that leads to the assembly of the 80S ribosome at the start
codon of themRNA (Pestova et al., 2001; Sonenberg and Hinnebusch,
2009). Eukaryotic cells and their viruses have evolved at least two
mechanisms for recruiting and positioning ribosomes during initia-
tion. The primary mechanism involves the recognition of the 5′cap
structure (m7GpppN) of mRNAs by eukaryotic translation initiation
factors (eIFs) which is followed by the binding of the 40S ribosomal
subunit and scanning downstream along the 5′untranslated region
(5′UTR) until the initiation codon is encountered (Pestova et al.,
2001; Sonenberg and Hinnebusch, 2009). Alternatively, numerous
viruses including, among others, Picornaviridae (Jackson et al., 1994;
Jang et al., 1988; Pelletier and Sonenberg, 1988), members of the
Flaviviridae (Hellen and Pestova, 1999; Pestova and Hellen, 1999),
and the Retroviridae (Balvay et al., 2007), as well as some eukaryotic
mRNAs utilize a cap-independent pathway (Hellen and Sarnow,ra).
l rights reserved.2001). In this mechanism, that bypasses the conventional scanning
pathway, an RNA element, the internal ribosome entry site (IRES),
drives ribosome recruitment and positioning on the message, either
at or just upstream of the start site (Hellen and Sarnow, 2001;
Jackson, 2005; Lopez-Lastra et al., 2005).
The precise molecular mechanism by which the cellular transla-
tional apparatus recognizes and modulates IRES activity is unknown
(Hellen and Sarnow, 2001; Jackson, 2005; Lopez-Lastra et al., 2005).
However, accumulating data strongly suggest that the IRES activity is
under the control of the canonical eIFs, as well as IRES-speciﬁc trans-
acting factors (ITAFs) (Belsham and Sonenberg, 1996; Semler and
Waterman, 2008; Spriggs et al., 2005; Stoneley and Willis, 2004). A
number of recent reports show that the ubiquitously expressed
member of the Elav (embryonic-lethal abnormal visual in Drosophila
melanogaster) family of RNA-binding proteins, HuR, participates in the
regulation of translation initiation and functions as an IRES regulatory
protein (Galban et al., 2008; Korf et al., 2005; Meng et al., 2005). HuR
inhibits IRES-mediated protein synthesis from the mRNAs of the
thrombomodulin (Yeh et al., 2008) and the type I insulin-like growth
factor receptor (IGF-IR) (Meng et al., 2005), while it enhances IRES-
mediated translation from the mRNA coding the hypoxia-inducible
factor (HIF)-1alpha (Galban et al., 2008). Interestingly, the human
Fig. 1. HuR represses translation initiation mediated by the HIV-1 IRES, while it
stimulated HCV IRES-driven protein synthesis. (A) The capped dl HIV-1 IRES RNA
(Brasey et al., 2003) was used to program G2/M (160 ng/μl) supplemented RRL in the
presence of increasing amounts (8 and 16 ng/μl) of in vitro transcribed, uncapped RNA
encoding HuR (Fan and Steitz, 1998). Luciferase activity was measured as indicated in
Material and methods. The FLuc/RLuc ratio was used as an index of IRES activity and
expressed as relative translational efﬁciency. The relative translational efﬁciency of the
dl HIV-1 IRES translated in supplemented RRL in the absence of HuR RNAwas arbitrarily
deﬁned as 1. (B) RRL was programmed with capped dl HCV IRES RNA (Barria et al.,
2009) and translated in the presence of increasing amounts (8 and 16 ng/μl) of in vitro
transcribed uncapped RNA encoding HuR. The FLuc/RLuc ratio was used as an index of
IRES activity and expressed as relative translational efﬁciency. The relative translational
efﬁciency of the dl HCV IRES translated in the absence of HuR RNA was arbitrarily
deﬁned as 1. (A and B) Values are the means±SEM from four independent
experiments. (C) HuR protein expression was detected in RRL by Western blotting
using monoclonal antibodies (Gallouzi et al., 2000; Voeltz et al., 2001). Actin was
detected by Western blotting as a loading control.
179A. Rivas-Aravena et al. / Virology 392 (2009) 178–185HuR protein has been reported to participate in the replication cycle of
the hepatitis C virus (HCV) and the human immunodeﬁciency virus
type 1 (HIV-1) (Korf et al., 2005; Lemay et al., 2008), two viruses
known to harbor IRES elements (Brasey et al., 2003; Buck et al., 2001;
Tsukiyama-Kohara et al., 1992). Furthermore, during HIV-1 antiviral
therapy HuR is responsible for inducing TNF-alpha and IL-6 expres-
sion, suggesting that the protein might have a direct impact on
atherosclerosis induced by HIV protease inhibitors (Zhou et al., 2007).
Jointly, these observations prompted us to explore whether HuR had
an additional role in HCV and HIV-1 IRES-mediated translation
initiation. Results presented in this study conﬁrm a previous report
showing that HuR is required for optimal HCV IRES activity (Korf et al.,
2005). Additionally, we show that HuR acts as a negative modulator of
the HIV-1 IRES and that its overexpression negatively impacts the late
stages of HIV-1 replication. Thus, this study yields novel insights into
the role of HuR in the post-transcriptional regulation of HCV and HIV-
1 gene expression.
Results and discussion
HIV-1 IRES activity is suppressed by HuR while HCV IRES activity
is enhanced
Since the ubiquitously expressed protein HuR has recently been
linked to the HIV-1 replication cycle (Lemay et al., 2008), and has also
been implicated in the regulation of IRES-driven translation (Galban
et al., 2008; Korf et al., 2005; Meng et al., 2005; Yeh et al., 2008), we
sought to investigate its potential role on protein synthesis mediated
by the HIV-1 IRES. This study was extended to include the HCV IRES as
it has been shown to require HuR for optimal activity (Korf et al.,
2005). In these assays the dual luciferase (dl) reporter construct
containing an upstream Renilla luciferase gene (RLuc) and a down-
stream Fireﬂy luciferase gene (FLuc) were used. Bicistronic constructs
harboring the HIV-1 (dl HIV-1 IRES) or the HCV (dl HCV IRES) IRES
have been previously described (Barria et al., 2009; Brasey et al.,
2003). In this bicistronic context IRES activity was monitored using
the FLuc activity as the readout, while the RLuc reporter gene served
as an upstream translational control. The use of these artiﬁcial
bicistronic mRNAs provides important advantages in this particular
study. First, they allow the HIV-1 IRES to be studied in the absence of
virus infection, thus eliminating potential interference from other
functions observed during the viral replication cycle where the RNA
region that harbors the IRES may also be involved (Berkhout, 1996;
Brasey et al., 2003). In addition, as the HIV-1 full-length mRNA
possesses a 5′cap structure and two IRES elements, all of which have
been reported capable of directing translation initiation from the same
initiation codon (Brasey et al., 2003; Buck et al., 2001; Ricci et al.,
2008), the isolation of each element seems necessary to characterize
their individual function and regulation. Secondly, bicistronic mRNAs
are ideal when studying the effect on translation initiation of a protein
such as HuR that can exert its function by affecting overall RNA
stability (Brennan and Steitz, 2001; Fan and Steitz, 1998; Gorospe,
2003), since variations in overall RNA concentration are not expected
to impact on the molar ratio between both cistrons (Jackson et al.,
1995). Thus, any variation in the FLuc/RLuc ratio (protein levels) will
directly reﬂect translation activity and not RNA stability (Jackson et al.,
1995).
In the ﬁrst series of experiments in vitro transcribed uncapped RNA
encoding HuR, synthesized from the pcDNA3-HuR plasmid (Fan and
Steitz, 1998), was co-translated in the rabbit reticulocyte lysate system
(RRL), as described in Materials and methods, with capped RNAs
generated from either the dl HIV-1 IRES (Fig. 1A) or the dl HCV IRES
(Fig. 1B) plasmids. The FLuc/RLuc ratio was used as an index of IRES
activity, with the mean translation efﬁciency of the control dl RNA
without HuR being arbitrarily set at 1 (±standard error). The addition
of 8 or 16 ng/μl of HuR RNA to the in vitro translation reaction reducedHIV-1 IRES activity by about 53% and 63%, respectively (Fig. 1A), while
it stimulated translation from the HCV IRES by about 42% and 120%,
respectively (Fig. 1B). HuR expression in RRL was visualized by
Western blot analysis (Fig. 1C). These ﬁndings conﬁrm a previous
report showing that HuR stimulates translation from the HCV IRES
(Korf et al., 2005) and suggest that in vitro overexpression of HuR has
antagonistic effects over the activities of the HIV-1 and HCV IRESes.
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results are comparable to what has been reported for other IRESes
which are negatively regulated by HuR (Meng et al., 2005; Yeh et al.,
2008).
We next sought to validate our observations in a different
experimental model. To this end Xenopus laevis oocytes nuclei were
microinjected with DNA corresponding to either the pcDNA3-HuR or
pcDNA3 plasmids 24 h prior to microinjection into the cytoplasm of
capped and polyadenylated dl ΔEMCV, dl HIV-1 IRES or dl HCV IRES
RNAs (Fig. 2A). The RLuc/FLuc bicistronic vector dl ΔEMCV, that
harbors a defective encephalomyocarditis virus (Δ-EMCV) IRES
known to inhibit ribosome reinitiation and readthrough, inserted
upstream of the FLuc reporter, was used as a negative control (Barria
et al., 2009; Brasey et al., 2003;Wilson et al., 2000b). Expression of the
human HuR protein in oocytes was conﬁrmed by Western blottingFig. 2. Human HuR negatively impacts HIV-1 IRES translation initiationwhile it stimulated H
were microinjected into Xenopus laevis oocyte nuclei (Fan and Steitz, 1998), followed, 24 h
corresponding to the dl ΔEMCV, dl HIV-1 IRES, or dl HCV IRES vectors (25 ng) as described i
processed. (A) Schematic representation of the experimental procedure is represented. Over
antibodies that recognize only the human version of the protein (Voeltz et al., 2001). (B) A rep
(O-2 to O-6) is shown. Actinwas detected byWestern blotting and used as a loading control.
data are expressed as relative luciferase activities, where the RLuc and FLuc activities of the dl
with pcDNA 3 plasmid (not expressing human HuR protein) were arbitrarily set to 1. Each vausing a well-characterized antibody known to speciﬁcally detect the
human version of the protein (Gallouzi et al., 2000; Voeltz et al.,
2001). As shown in Fig. 2B expression of HuR was not equal in all
injected oocytes; thus, all oocytes that by Western blot analysis
revealed detectable amounts of human HuR were used in the assay.
RLuc and FLuc activities were measured and expressed as relative
values (see explanation in the legend of Fig. 2). In agreement with
what was observed in RRL, cap-dependent translation initiation,
monitored by RLuc activity, was not affected by HuR expression (Fig.
2C). However, and as shown above in our in vitro experiments, the
expression of HuR in X. laevis oocytes had a negative impact on HIV-1
IRES activity, while it stimulated HCV IRES-mediated translation
initiation (Fig. 2C). It seems reasonable to discard the possibility that
the effect of HuR over FLuc protein synthesis is due, in the case of the
HIV-1 IRES, to mRNA destabilization or relocation to translationallyCV IRES activity in Xenopus laevis oocytes. The pcDNA3 or pcDNA3-HUR plasmid (35 ng)
later, by microinjection into the oocyte cytoplasm of capped and polyadenylated RNA
n Material and methods. Oocytes were harvested 24 h after the last microinjection and
expression of HuR was evaluated in each egg byWestern blotting using monoclonal HuR
resentativeWestern blot showing the variations of HuR expression in 5 different oocytes
(C) Renilla luciferase (RLuc) and Fireﬂy luciferase (FLuc) activities were determined and
HIV-1 IRES (left panel), and dl HCV IRES (right panel) RNAs in the oocytes microinjected
lue is the mean±SEM from at least 6 oocytes obtained from two different animals.
Fig. 3. HeLa cell endogenous HuR negatively affects translation mediated by the HIV-1
IRES, while it is required for optimal HCV IRES-driven protein synthesis. HeLa cells were
transfected with either the control (siRNA-C) or the siRNA-HuR small interfering RNAs.
Cells were then transfected 48 h later with 1.5 μg of dl ΔEMCV, dl HIV-1 IRES, or dl HCV
IRES plasmids (Barria et al., 2009; Brasey et al., 2003; Wilson et al., 2000b). Cells were
processed 24 h after the second transfection. (A) Total RNAwas extracted from cells and
used as template in a non-quantitative one-step RT-PCR designed to amplify the full-
length bicistronic RNAs [(+) RT-reaction; bottom panel]. As a control for DNA
contamination the same reactionwas conducted without a step of reverse transcription
[(−) RT-reaction; bottom panel]. A schematic representation of the experimental
procedure indicating the used primers (arrows) is presented (top panel). (B) HuR and
tubulin proteins were detected by Western blotting using monoclonal antibodies
(Voeltz et al., 2001). Gaps indicate where intervening lanes have been spliced out. (C)
RLuc and FLuc activities were measured and the [(FLuc/RLuc)/total protein] ratio was
used as an index of IRES activity. The use of the (FLuc/RLuc) ratio makes the analysis
independent from the concentration of bicistronic RNA in each independent repetition
(Jackson et al., 1995). The [(FLuc/RLuc)/total protein] of the dl ΔEMCV vector was
arbitrarily set to 1. Values are the means±SEM from three independent experiments.
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of HCV IRES, as HuR has no discernable effect over the protein levels of
RLuc, the upstream cistron of our bicistronic mRNA. Importantly, as
these RNAs were directly microinjected into the cytoplasm of oocytes,
our data not only conﬁrm that HuR has opposite effects on the
translational activities of the HIV-1 and HCV IRESes, but also suggest
that HuR does not require the targeted RNA to have prior exposure to
the nucleus.
We next assessed whether HuR can function as a regulator of
protein synthesis mediated by the HIV-1 and HCV IRESes in cells. We
reasoned that if endogenous HuR participates in the modulation of
HIV-1 and HCV IRES activity in cells its knockdown would impact
positively on HIV-1 IRES activity, while it would have a negative effect
on the HCV IRES. Experiments were conducted in HeLa cells as both
IRESes are active in these cells (Borman et al., 1997; Brasey et al.,
2003), and endogenous expression of HuR in HeLa cells is relatively
high (Fan and Steitz, 1998). The dual luciferase plasmid dl ΔEMCV, dl
HIV-1 IRES, or dl HCV IRES was transfected into HeLa cells while
endogenous HuRmRNAwas targeted using a speciﬁc siRNA. An earlier
study showed that the HCV 5′UTR displays a promoter activity
(Dumas et al., 2003). Thus, we ﬁrst evaluated the presence of the full-
length bicistronic RNA in transfected cells. To achieve this, total RNA
was extracted from cells and analyzed by RT-PCR (Fig. 3A) as
previously described (Herbreteau et al., 2005; Kazadi et al., 2008).
Even though results do not rule out the presence of other RNA species,
they do conﬁrm, in all cases, the presence of the full-length bicistronic
mRNA in cells expressing or not HuR protein (Fig. 3A). Western blot
analysis revealed that transfection of HuR siRNA (siRNA-HuR; Fig. 3B,
lanes 4–6) resulted in a dramatic decrease in the levels of endogenous
HuR (Fig. 3B, compare lanes 1–3 with lanes 4–6). Consistent with our
in vitro data siRNA-mediated knockdown of endogenous HuR was
accompanied by an increase in HIV-1 IRES-mediated protein synthesis
(Fig. 3C). While predictably and conversely, reduction of endogenous
HuR resulted in decreased HCV IRES activity (Fig. 3C). Thus, we
concluded that endogenous HuR differentially modulates HIV-1 and
HCV IRES activities, acting as a negative regulator of HIV-1 IRES-driven
translation initiation while positively affecting the activity of HCV
IRES.
HuR overexpression impairs post-integration steps of the HIV-1
replication cycle
HuR is one of the best-studied examples of an ARE-binding protein
(Brennan and Steitz, 2001). ARE elements have been classiﬁed into
three groups based on distinct sequence features and functional
properties (Barreau et al., 2005). Close analysis of the HIV-1 and HCV
5′UTR sequences do not reveal any of the well-characterized ARE
element targets for HuR. Consistent with this observation and in
agreement with previous reports (Lemay et al., 2008; Spangberg et al.,
2000), we were unable to demonstrate the direct binding of HuR to
the HIV-1 5′UTR, to the HCV 5′UTR, or to the ΔEMCV regions in
isolation or in the context of RLuc/FLuc bicistronic mRNA. This
whether using recombinant HuR protein, RRL-synthesized HuR
protein or overexpression of HuR in X. laevis oocytes and in HeLa
cells (data not shown). These ﬁndings suggest that the effect of HuR
on HIV-1 and HCV IRES-mediated translation initiation does not
involve direct binding to the IRES or to the vector RNA. Alternatively,
this could imply that HuR requires speciﬁc conditions to bind the HIV
and HCV IRES elements (Meng et al., 2008). Modulation of the IGF-IR
IRES by HuR is differentially regulated by dynamic, competitive
interactions of HuR with other speciﬁc RNA-binding proteins that
occur under particular physiological conditions (Meng et al., 2008).
Next we sought to determine the biological relevance of our
ﬁndings. For this, we examined if HuR protein inﬂuences HIV-1 virus
replication. In this series of experiments we exclusively focused on
HIV-1 as we lack an adequate system to replicate HCV in cell culture.
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replication (Lemay et al., 2008); direct binding to the HIV-1 reverse
transcriptase (RT) enhances its activity (Lemay et al., 2008).
Interestingly, and in agreement with the results presented herein,
Lemay et al. (2008) showed that siRNA directed against endogenous
HuR slightly increases the generation of infectious particles from HIV-
1 producing HeLa cell lines (Fig. 4C in reference (Lemay et al., 2008)).
Based on these ﬁndingswe decided to do the opposite experiment and
evaluated HIV-1 production in HeLa cells under conditions in which
the HuR protein was overexpressed. HeLa cells were co-transfected
with the pNL4.3 provirus, with the vector alone or expressing HuR.Fig. 4. HuR protein overexpression negatively impacts on post-integration steps of the H
provirus pNL4.3 (200 ng) together with vector alone (400 ng) or the vector expressing Hu
viral particles produced by HeLa cells in the cell supernatant was quantiﬁed 24 h post-tran
ml (Vironostika HIV-1 Antigen, Biomérieux). The negative control (−) corresponds to th
represent three independent DNA transfection experiments (±standard deviation). (B) T
pNL4.3 (200 ng) and vector alone (200 ng) or the vector expressing HuR (200 ng) by ultra
Western blotting using a polyclonal antibody as indicated in Materials and methods. Th
transfected with the pNL4.3 vector. (C) Total protein was extracted from HeLa cells co-tran
(200 ng), 20 μg of total protein was resolved on a 12% SDS-PAGE as described in Materials
from HeLa cells co-transfected with pNL4.3 (200 ng) and vector alone (200 ng) or the vect
PCR as indicated in Materials and methods. The viral RNA (vRNA) quantity in pNL4.3 cells t
three independent experiments.Direct transfection of pNL4.3 enabled us to bypass the reverse trans-
cription step and focus exclusively on the post-integration steps of the
HIV-1 replication cycle. The HeLa cells used in these assays lack the
receptors and co-receptors required for de novo HIV-1 infection. Virus
productionwas assessed by a standard ELISA quantiﬁcation of the Gag
CA-p24 antigen in the cell supernatant (Fig. 4A), and data were
conﬁrmed by direct visualization of viral CA-p24 by Western blot
analysis (Fig. 4B). Co-transfection of pNL4.3 provirus and the vector
expressing HuR caused an important reduction in Gag CA-p24 antigen
concentration in supernatants (Fig. 4A). To further challenge our
observations total protein and RNA was extracted from cellsIV-1 replication cycle in HeLa cells. HeLa cells were co-transfected with the HIV-1
R protein (200 ng and 400 ng) (Fan and Steitz, 1998). (A) Gag CA-p24 antigen of the
sfection using a commercial ELISA kit and are expressed in international units (UI) per
e supernatant of HeLa cells that were not transfected with the pNL4.3 vector. Data
otal virus was concentrated from the supernatants of HeLa cells co-transfected with
centrifugation as described in Materials and methods. HIV-1 CA-p24 was detected by
e negative control (−) corresponds to the supernatant of HeLa cells that were not
sfected with pNL4.3 (200 ng) and vector alone (200 ng) or the vector expressing HuR
and methods and actin was detected by Western blotting. (D) Total RNA was isolated
or expressing HuR (200 ng or 400 ng). HIV-1 RNAwas quantiﬁed using a speciﬁc qRT-
ransfected with vector alone was arbitrarily set to 1. Values are the means±SEM from
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(Figs 4C and D). Actin was detected by Western blot as shown in Fig.
4C. Viral RNA was quantiﬁed by a speciﬁc qRT-PCR reaction as
described inMaterials andmethods. An apparent increase of viral RNA
was observed when HuR was overexpressed however data revealed
not to be statistically signiﬁcant (one-way ANOVA followed by
Bonferroni post-ANOVA test). Therefore, the results presented in
Figs. 4C and D suggest that the effect of HuR over HIV-1 replication is
not exerted at the level of cell viability nor HIV-1 RNA transcription.
Thus, despite being unable to demonstrate protein–RNA interaction,
in agreement with our previous results generated using bicistronic
mRNAs, HuR overexpression exerts a negative impact on post-
integration steps of the HIV-1 replication cycle.
In cells HuR engages in several protein–protein complexes that
are not mediated by RNA (Brennan et al., 2000). Interestingly, the
function of RNA-binding proteins such as HuR is altered depending
of the partner-protein to which it binds (Brennan et al., 2000).
Thus, it is conceivable that HuR–ligand interaction may alter the
afﬁnity of both proteins for their target RNAs. Based on this
possibility we propose that the regulation of HIV-1 IRES-driven
protein synthesis by HuR is mediated by an as yet unidentiﬁed
HuR–ligand that would act as an ITAF for the HIV-1 IRES (depicted
as L in Fig. 5). A similar ligand-model has been proposed to explain
the HuR induced activation of the IRES present within the 5′UTR of
the IGF-IR mRNA (Meng et al., 2008; Meng et al., 2005). Thus, IRES
function would be differentially regulated by dynamic, competitive
interactions with multiple speciﬁc RNA-binding proteins (Meng et
al., 2008). In the case of the HIV-1 IRES we speculate that the
HuR–L complex (Fig. 5) cannot act as an ITAF for the HIV-1 IRES.
Interestingly, a similar model has been proposed to explain the
effect of HuR on early steps of HIV-1 replication (Lemay et al.,
2008). The human HuR protein interacts with HIV-1 reverse
transcriptase and modulates reverse transcription in infected cells
(Lemay et al., 2008). Interestingly, stimulation of reverse transcrip-
tion is not mediated by HuR binding to the viral RNA (Lemay et al.,
2008). In consequence, our study suggests that the human HuR
protein modulates the HIV-1 replication cycle through protein–
protein and not protein–RNA interactions.Fig. 5. HuR indirectly blocks HIV-1 IRES-mediated translation. Results presented in this study
Our current workingmodel posits that a yet unidentiﬁed HuR–ligand protein (depicted as L) i
is unable to act as an ITAF for the HIV-1 IRES hampering viral IRES-mediated translation in
indicating that the function of RNA-binding protein is altered depending of the partner-pro
engages in several protein–protein complexes that are not mediated by RNA (Brennan et alMaterials and methods
Plasmids
Vector dl HIV-1 IRES corresponds to the dual luciferase plasmid
harboring the full HIV-1 5′UTR (nt 1-336) described in Brasey et al.
(2003) (Brasey et al., 2003). Plasmid dl HCV IRES and dl ΔEMCV
plasmids were described in earlier reports (Barria et al., 2009; Brasey
et al., 2003; Wilson et al., 2000a; Wilson et al., 2000b), as well as
plasmids used for HuR expression pcDNA3-HuR and pGEX-5X-2/HuR
(Fan and Steitz, 1998; Gallouzi et al., 2000).
Cell culture, cell cycle arrest and virus production
HeLa cells were cultured in Dulbecco's modiﬁed Eagle's medium
(Gibco-BRL, Invitrogen, Life Technologies Corporation, Carlsbad,
California, USA, or Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 10% (v/v) fetal bovine serum (Hyclone, Logan, UT, USA, or Sigma-
Aldrich, St. Louis, MO, USA), 50 U of penicillin–streptomycin/ml
(Gibco-BRL, Invitrogen, Life Technologies Corporation, Carlsbad,
California, USA, or Sigma-Aldrich, St. Louis, MO, USA), and when
needed with sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA) at
37 °C in 5% CO2 humidiﬁed air. To induce G2/M arrest, HeLa cells were
incubated for 18 h in medium containing 0.4 μg/ml of nocodazole
(Sigma-Aldrich, St Louis, MO, USA) as previously described (Brasey et
al., 2003). Cell cycle arrest was evaluated by ﬂow cytometry (Brasey et
al., 2003).
HIV-1 particles were produced by transfecting HeLa cells (CCL 2.2,
ATCC) with the pNL4.3 provirus (gene bank accession: AF324493).
Viral particle production in the cell supernatant was evaluated with
the anti-p24 ELISA kit from Biomérieux (Vironostika HIV-1 Antigen;
bioMérieux SA, Marcy l'Etoile, France) following the manufacturer's
protocol. Total virus present in 1.5 ml of supernatant was concentrated
by ultracentrifugation at 200,000 ×g for 1 h. The virus-containing
pellet was resuspended in 25 μl of diluting buffer (60 mM Tris/HCl pH
80, 180 mM KCl; 6 mM MgCl2, 0,6 mM EGTA ph8, 1% Triton X-100). A
total volume of 5 μl of resuspended viral particles were directly mixed
with standard Leamli buffer and resolved on a 12% SDS-PAGE. HIV-1suggest that HuR exerts its effect on HIV-1 IRES activity without binding the viral RNA.
s required for HIV-1 IRES activity (A). However, when in complexwith HuR the L protein
itiation (B). This model is based on the herein presented data (Figs. 1–4), observations
tein to which they bind (Brennan et al., 2000), and on data showing that in cells HuR
., 2000).
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kindly provided by Dr. A. Mouland (McGill University). Blots were
developed as described below.
In vitro RNA synthesis and in vitro translation
The dual luciferase plasmids dl ΔEMCV, dl HIV-1 IRES digested
with BamHI (Fermentas) and the dl HCV IRES digested with NotI
(Fermentas, Vilnius, Lithuania) served as templates to generate
bicistronic RNAs used in the in vitro translation assays. Capped RNAs
were synthesized using the mMessage mMachine T7 System (Applied
Biosystems/Ambion, Austin, TX, USA), while capped and polyadeny-
lated RNA transcripts were synthesized using the complete mMessage
mMachine T7 Ultra Kit which includes the reagents for poly(A) tailing
(Applied Biosystems/Ambion, Austin, TX, USA) according to the
manufacturer's protocol. The integrity of the RNAs was conﬁrmed by
electrophoresis on denaturing agarose gels and their concentration
quantiﬁed by spectrophotometry (GeneQuant, GE Healthcare, Piscat-
away, NJ, USA.). In vitro transcribed dl HIV-1 IRES RNAs (10 ng/μl
except otherwise indicated) were translated in 25% (v/v) nuclease
treated rabbit reticulocyte lysate (RRL; Promega Corporation, Madi-
son, WI, USA) supplemented with cell extracts at adequate salt
concentrations (Anderson and Lever, 2006; Brasey et al., 2003). HeLa
cell extracts from G2/M arrested cells were prepared as previously
described (Brasey et al., 2003) maintaining ﬁnal salt concentrations,
but without addition of creatine kinase, creatine phosphate, spermi-
dine, GTP, ATP, and amino acids. G2/M-HeLa extracts were pre-
incubated with RNA for 5 min prior addition of the RRL mix. The dl
HCV IRES and dl ΔEMCV RNA were translated in RRL according to
Barria et al. (2009). The translation reactions were conducted for
90 min at 30 °C, unless otherwise speciﬁed in the ﬁgure legends.
siRNA induced HuR knockdown and immunoblotting
To knockdown endogenous HuR in HeLa cells, we used the small
interfering RNA (siRNA) duplexes as described (Dormoy-Raclet et al.,
2007). Cells plated in six-well plates were grown overnight. The
following day, cells were transiently transfected with 0.12 μMof either
the control (siRNA-C) or the siRNA-HuR in OPTI-MEM I Reduced
Serum Medium (Invitrogen, Life Technologies Corporation, Carlsbad,
California, USA) using Lipofectamine Plus (Invitrogen, Life Technolo-
gies Corporation, Carlsbad, California, USA) according to the manufac-
turer's instructions. After 48 h, cells were transfected with 1.5 μg of dl
ΔEMCV, dl HIV-1 IRES, and dl HCV IRES plasmids. Samples were
processed 24 h after plasmid transfection. To conﬁrm HuR knockdown
5 μg of total cell extracts were resolved on a 12% SDS-polyacrylamide
gel. Total cell extracts were prepared as described in Dormoy-Raclet et
al. (2007). For immunoblotting, proteins were transferred to nitro-
cellulose membranes (Bio-Rad Laboratories Headquarters, Hercules,
CA, USA) and probed with HuR monoclonal (1:10,000 dilution)
(Voeltz et al., 2001), and anti-tubulin monoclonal (Sigma-Aldrich, St.
Louis, MO, USA; 1:5000 dilution), or anti-actin monoclonal (MP
Biomedicals, Solon, OH, USA; 1:5000 dilution) with horseradish
peroxidase-conjugated goat anti-mouse as secondary antibodies (GE
Healthcare, Piscataway, NJ, USA). Blots were developed with the
Amersham enhanced chemiluminescence system.
Luciferase assays
The activities of Fireﬂy and Renilla luciferases in lysates prepared
from RRL, X. laevis oocyte, or transfected cells were measured using a
dual luciferase reporter system assay (Promega Corporation, Madison,
WI, USA), on 30 μl of cell lysates, or 1–5 μl of X. laevis oocyte lysate (see
below), or 1 μl of complemented RRL using a Berthold DS Sirius
luminometer.Oocyte harvesting, and microinjection
Oocytes were isolated from X. laevis ovarian fragments by
manual dissection as previously described (Acuna-Castillo et al.,
2002). To evaluate viral IRES activity in oocytes, 25 ng of in vitro
transcribed, capped and polydenylated RNA (see above) was
microinjected into each oocyte with glass micropipettes calibrated
to deliver a ﬁnal volume of 50 nl. Control injections were conducted
for each experimental set using oocytes from the same animals. To
assess the effect of HuR, oocytes were ﬁrst microinjected with
35 ng of either pcDNA3 control vector (Invitrogen, Life Technologies
Corporation, Carlsbad, California, USA) or pcDNA3-HuR and micro-
injected 24 h later with 25 ng of in vitro transcribed, capped and
polyadenylated bicistronic RNA generated from either dl ΔEMCV, dl
HIV-1 IRES or dl HCV IRES plasmids. Oocytes were incubated for
24 h at 15 °C in standard Barth's solution supplemented with 10 UI/
l penicillin–streptomycin and 2 mM pyruvate. Oocyte lysates were
prepared in 1× Passive Lysis Buffer (Promega Corporation, Madison,
WI, USA), centrifuged at 16,000 ×g for 5 min, and 1–5 μl of
supernatant was used in the detection assay (see above). Western
bots were conducted using 20 μg of total protein as described
above.
Protein expression and puriﬁcation
The fusion protein GST-HuR and protein GST were expressed and
puriﬁed as previously described (Brennan et al., 2000; Gallouzi et al.,
2000). Plasmids for bacterial expression pGEX-5X-2/HuR (Brennan et
al., 2000; Gallouzi et al., 2000), and pGEX-5X-2 (Amersham
Pharmacia Biotech AB) were transformed into Escherichia coli BL21
(DE3) cells. Cell growth, induction and lysis were performed following
well established procedures (Frangioni and Neel, 1993). The puriﬁca-
tion of GST and HuR-GST fusion protein was conducted according to
Brennan et al. (2000) and Gallouzi et al. (2000).
RNA extraction, RT-PCR and real time RT-PCR
Cells were collected by centrifugation at 710 ×g for 5 min and
washed three times in phosphate-buffered saline (PBS; 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7H2O, 1.4 mM KH2PO4, pH 7.4)
at 4 °C. RNA was extracted from cells using the Trizol reagent
(Invitrogen, Life Technologies Corporation, Carlsbad, California,
USA), treated with RNase free DNase RQ1 (Promega Corporation,
Madison, WI, USA), and its integrity was monitored by electrophor-
esis on denaturing agarose gels and quantiﬁed by spectrophotome-
try (NanoDrop Technology, Wilmington, Delaware, USA). The
RT-PCR assay to conﬁrm the presence of the bicistronic RNA was
carried out using the SuperScript™ III One-Step RT-PCR System with
Platinum® Taq DNA polymerase kit (Invitrogen, Life Technologies
Corporation, Carlsbad, California, USA) according to the manufac-
turer's protocol, using 3 μg of total RNA and primers p2anti (5′-
TCTCTTCATAGCCTTATGCAGTTG-3′) and Pforluc (5′-CATGACTTC-
GAAAGTTTATGATC-3′). As a control for DNA contamination the
same reaction was conducted without the step of RT. The amount of
viral RNA present within cells was evaluated by a quantitative real
time RT-PCR reaction (qRT-PCR) using the forward primer 5′ GCGC-
TGCTAGCGGGTCTCTCTGGTTAGACCAGATCTGAGC ′3 and the reverse
primer 5′ GCGCTACCGGTCTCTCTCCTTCTAGCCTCCGCTAGTCAA ′3,
designed to speciﬁcally amplify the 5′UTR of the HIV-1 RNA (based
on pNL4.3; AF324493). qRT-PCR reactionwere programmed with 3 μg
of total cellular RNA and conducted on a Stratagene MX 3000
instrument (Stratagene, La Jolla, CA, USA), using the Brilliant® II
SYBR® Green QRT-PCR Master Mix KIT (Stratagene). The number of
HIV-1 RNA copies were normalized to those of human 18S RNA by an
external standard curve showing a linear distribution (r: 0.99)
between 10 and 1×106 copies. The 18S RNA was ampliﬁed using the
185A. Rivas-Aravena et al. / Virology 392 (2009) 178–185forward primer 5′ GATATGCTCATGTGGTGTTG ′3 and reverse primer
5′ AATCTTCTTCAGTCGCTCCA ′3.
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